Trial Profile
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Nov 2023
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Sarcoma
- Focus Therapeutic Use
- 08 Nov 2023 Planned End Date changed from 1 May 2028 to 1 May 2033.
- 08 Nov 2023 Planned primary completion date changed from 1 May 2028 to 1 May 2026.
- 26 Jun 2023 Status changed from recruiting to active, no longer recruiting.